...
首页> 外文期刊>Bone marrow transplantation >Renal dysfunction within 90 days of FluBu4 predicts early and late mortality
【24h】

Renal dysfunction within 90 days of FluBu4 predicts early and late mortality

机译:Flubu4的90天内肾功能障碍预测早期和晚期死亡率

获取原文
获取原文并翻译 | 示例

摘要

Myeloablative conditioning regimens with significant extramedullary toxicity result in high rates of renal dysfunction including acute kidney injury (AKI). Here we examine the incidence and impact of a reduced creatinine clearance (below 60 ml/min) before day 90 (early renal dysfunction, ERD) in patients receiving the reduced toxicity fludarabine/i.v. busulfan (FluBu4) regimen prior to allogeneic transplant. Of 91 patients receiving FluBu4, 62 (68%) developed ERD. ERD resulted in worse overall survival (OS, 2.2 years versus median not reached, p = 0.04) and progression-free survival (PFS, 1.6 years versus median not reached, p = 0.02). This was due to a higher relapse rate (34% versus 14%, p = 0.03) in the ERD group. In time-dependent Cox proportional hazards models adjusted for age, ERD was associated with worse OS (hazard ratio [HR] 2.67, 95% confidence interval [CI] 1.06-4.21, p = 0.043) and PFS (HR 2.52, 95% CI 1.17-4.28, p = 0.030). Patients with ERD surviving 1 year had an increased risk of chronic kidney disease (CKD, OR 10; 95% CI 1.4-112.6, p = 0.0181), which was associated with worse survival (3.2 years versus median not reached, p = 0.002). ERD after FluBu4 is therefore a poor prognostic sign resulting in increased relapse, worse OS, and high risk of CKD at 1 year.
机译:具有显着髓外毒性的肌髓性调理方案导致肾功能障碍的高率,包括急性肾损伤(AKI)。在这里,我们在接受毒性降低的毒性氟尿布/ I.V的患者之前检查肌酐清除(低于60毫升/分钟)的发病率和影响。 Busulfan(Flubu4)在同种异体移植之前的方案。 91例接受Flubu4,62(68%)的患者发达了ERD。 ERD导致总体生存率更差(OS,2.2岁,未达到,P = 0.04)和无进展的生存(PFS,1.6岁,与中位数没有达到,P = 0.02)。这是由于ERD组中较高的复发率(34%,P = 0.03)。在时间依赖于时间的COX比例危险模型,调整为年龄,ERD与更差的OS(危险比[HR] 2.67,95%置信区间[CI] 1.06-4.21,P = 0.043)和PFS(HR 2.52,95%CI)有关1.17-4.28,p = 0.030)。 ERD患者存活1年的慢性肾疾病风险增加(CKD,或10; 95%CI 1.4-112.6,P = 0.0181),其与更严重的存活相关(3.2岁,与中位数未达到,P = 0.002) 。因此,霉菌4之后的预后迹象差,导致复发增加,OS更差,1年的CKD风险高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号